OncoMatch/Clinical Trials/NCT05069857
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Is NCT05069857 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab (anti-PD-1 inhibitor) and Apatinib (anti-VEGFR inhibitor) for oral squamous cell carcinoma.
Treatment: Camrelizumab (anti-PD-1 inhibitor) · Apatinib (anti-VEGFR inhibitor) — To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression > 10 CPS (CPS score > 10)
The combined positive score (CPS score) of PD-L1 expression > 10
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 3,000/mm3, hemoglobin ≥ 8g/L, platelet ≥ 80,000/mm3
Kidney function
serum creatinine ≤ 1.5 times the normal upper limit
Liver function
ALAT/ASAT ≤ 2.5 times the normal upper limit, bilirubin ≤ 1.5 times the normal upper limit
Cardiac function
No obvious cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome, ≥ grade 2 heart disease diagnosed according to the NYHA classification criteria within 3 months prior to enrollment)
Blood routine examination: WBC < 3,000/mm3, hemoglobin < 8g/L, platelet < 80,000/mm3; Liver function: ALAT/ASAT > 2.5 times the normal upper limit, bilirubin > 1.5 times the normal upper limit; Renal function: serum creatinine > 1.5 times the normal upper limit; Obvious cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome, ≥ grade 2 heart disease diagnosed according to the NYHA classification criteria within 3 months prior to enrollment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify